- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
Patent holdings for IPC class C07D 233/61
Total number of patents in this class: 387
10-year publication summary
|
22
|
17
|
24
|
24
|
17
|
17
|
28
|
10
|
26
|
23
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3304 |
7 |
| BIAL - Portela & CA, S.A. | 214 |
6 |
| PTC Therapeutics, Inc. | 475 |
6 |
| Bristol-myers Squibb Company | 4742 |
5 |
| Centre National de La Recherche Scientifique | 11023 |
5 |
| Agency for Science, Technology and Research | 3733 |
5 |
| Dana-Farber Cancer Institute, Inc. | 2664 |
5 |
| Institut Curie | 615 |
5 |
| Seren Technologies Limited | 9 |
5 |
| AstraZeneca AB | 2814 |
4 |
| Merck Patent GmbH | 5728 |
4 |
| Bayer Pharma AG | 1014 |
4 |
| President and Fellows of Harvard College | 6094 |
4 |
| Takeda Pharmaceutical Company Limited | 2712 |
4 |
| EA Pharma Co., Ltd. | 96 |
4 |
| Tetraphase Pharmaceuticals, Inc. | 52 |
4 |
| Toyama Chemical Co., Ltd. | 88 |
4 |
| The United States Government AS represented by The Department of Veterans Affairs | 1329 |
4 |
| Universite de Montpellier | 1042 |
4 |
| Nissan Chemical Corporation | 2227 |
4 |
| Other owners | 294 |